OncoDaily Medical Journal (ODMJ) welcomes a range of manuscript types that reflect the diversity of research, clinical practice, and scholarly discussion in oncology. Authors are expected to select the most appropriate category for their submission and ensure that their manuscript adheres to the specific requirements outlined below. Word limits refer to the main text unless otherwise indicated.

Original Research Articles form the core of the journal and present novel findings from clinical, translational, or basic oncology research. These manuscripts should be structured in a standard format, including Introduction, Methodology, Results, Discussion and Conclusion. The main text should not exceed 4,000 words and must include a structured abstract of up to 300 words. Authors may include up to 8 tables and/or figures and up to 100 references.

Clinical Studies and Clinical Trials report interventional or observational clinical research, focusing on study design, methodology, outcomes, and their relevance to clinical practice. These submissions follow the same formatting and length requirements as Original Research Articles, with a maximum of 4,000 words, a structured abstract of up to 300 words, up to 8 tables and/or figures, and up to 100 references.

Review Articles, including Narrative Reviews, Systematic Reviews, and Meta-Analyses, provide comprehensive overviews and critical evaluations of the existing literature. These manuscripts may be up to 5,000 words in length and should include an abstract of up to 300 words. A maximum of 5 tables and/or figures and up to 120 references are permitted.

For Systematic Reviews and Meta-Analyses, authors must clearly describe the search strategy, eligibility criteria, study selection process, and methods of data extraction and synthesis to ensure transparency and reproducibility. Authors should follow the PRISMA 2020 reporting guidelines. Systematic Reviews and Meta-Analyses should be prospectively registered in PROSPERO when eligible. If PROSPERO registration is not applicable, authors are encouraged to register the review protocol in another publicly accessible registry, such as the Open Science Framework (OSF). The registry name and registration number or persistent identifier should be provided in the manuscript.

Short Reports or Brief Communications present concise accounts of preliminary findings, smaller-scale studies, or negative results that contribute meaningful insights to the field. These manuscripts should not exceed 2,000 words and must include an abstract of up to 200 words. Authors may include up to 4 tables and/or figures and up to 20 references.

Case Reports and Case Series describe unique or rare clinical cases, unusual disease presentations, or innovative management strategies that offer important clinical insights. These submissions should be limited to 1,500 words, accompanied by an abstract of up to 275 words. Up to 3 tables and/or figures and up to 20 references are allowed.

Perspectives, Opinions, and Commentaries provide expert viewpoints on emerging topics, ongoing debates, or challenges in oncology. These articles may be up to 2,000 words in length. An abstract is optional and, if included, should be unstructured. Authors may include one table or figure and up to 20 references.

Correspondence, including Letters to the Editor, consists of brief communications such as comments on published articles, scientific observations, or responses to previously published work. These submissions should be concise, with a maximum length of 500 words. Abstracts are not required. Authors may include one table or figure and up to 5 references. Correspondence is generally subject to peer review, depending on its content and relevance.

Editorials offer succinct discussions of timely issues, recent advances, or policy-relevant topics in oncology. These articles do not have a fixed word limit and do not require an abstract. The inclusion of tables, figures, and references is at the discretion of the authors and editors, depending on the nature of the topic.

Trials in Progress articles describe the rationale, design, and methodology of ongoing or planned oncology clinical trials. These submissions should present the study background, objectives, trial design, patient population, interventions, endpoints, and clinical trial registration details. Results should not be included, as the trial is still ongoing or not yet completed. Trials in Progress articles should not exceed 1,000 words. Authors may include one figure and up to 10 references. These submissions are subject to peer review.

Protocols describe the rationale, objectives, design, and planned methodology of clinical or other research studies before completion of the study or analysis of its primary results. These manuscripts should clearly present the study background, objectives, study design, participant population and eligibility criteria, interventions or procedures where applicable, outcome measures, statistical analysis plan, ethical considerations, and registration information.
Protocols for randomized clinical trials should follow the SPIRIT 2025 reporting guidelines and include the clinical trial registration number. Protocols for systematic reviews and meta-analyses should follow PRISMA-P and include registration information, such as a PROSPERO registration number or another persistent registry identifier, where applicable.
Results should not be included, as the study has not yet been completed. Protocol manuscripts should not exceed 3,000 words, may include up to 4 tables and/or figures, and up to 50 references. These submissions are subject to peer review.

Authors are encouraged to follow these guidelines carefully to ensure a smooth review process and timely consideration of their manuscripts.